Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet

A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota

(2018) Li Zhao et al.   Frontiers in Endocrinology

Identification of therapeutic effect of glucagon-like peptide 1 in the treatment of STZ-induced diabetes mellitus in rats by restoring the balance of intestinal flora

(2018) Xiao Yuan et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Liraglutide modulates gut microbiota and reduces NAFLD in obese mice

(2018) GV Moreira et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Featured article: Structure moderation of gut microbiota in liraglutide-treated diabetic male rats

(2017) Qian Zhang et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

The Effect of Probiotic and/or Prebiotic on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease: A Double Blind Randomized Clinical Trial

(2017) Leila Javadi et al.   Iranian Red Crescent Medical Journal

Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study

(2016) Jean-Michel Petit et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

The role of the gut microbiota in NAFLD

(2016) Christopher Leung et al.   Nature Reviews Gastroenterology & Hepatology

Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment

(2016) Lin Wang et al.   Scientific Reports

NAFLD: A multisystem disease

(2015) Christopher D. Byrne et al.   JOURNAL OF HEPATOLOGY

Increased androgen levels in rats impair glucose-stimulated insulin secretion through disruption of pancreatic beta cell mitochondrial function

(2015) Hongdong Wang et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

(2015) Xavier Pi-Sunyer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway

(2015) YAN-GUI WANG et al.   Experimental and Therapeutic Medicine

GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody

(2014) Charles Pyke et al.   ENDOCRINOLOGY

Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice

(2014) Jingjing Wang et al.   ISME Journal

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease

(2014) Changtao Jiang et al.   JOURNAL OF CLINICAL INVESTIGATION

The serine protease prostasin regulates hepatic insulin sensitivity by modulating TLR4 signalling

(2014) Kohei Uchimura et al.   Nature Communications

Non-alcoholic fatty liver disease

(2014) N. Sattar et al.   BMJ-British Medical Journal

A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome

(2013) Shuiming Xiao et al.   FEMS MICROBIOLOGY ECOLOGY

Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults

(2013) M E J Lean et al.   INTERNATIONAL JOURNAL OF OBESITY

Effect of Lipopolysaccharide on Inflammation and Insulin Action in Human Muscle

(2013) Hanyu Liang et al.   PLoS One

GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic MaleApoE−/−Mice

(2012) Naim Panjwani et al.   ENDOCRINOLOGY

Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial

(2012) Carmela Loguercio et al.   FREE RADICAL BIOLOGY AND MEDICINE

Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH

(2012) Lixin Zhu et al.   HEPATOLOGY

Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

(2012) Daniel J. Cuthbertson et al.   PLoS One

The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone

(2012) Takamasa Ohki et al.   TheScientificWorldJOURNAL

Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms

(2011) Anna Iacono et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

TLR4 and Insulin Resistance

(2010) Jane J. Kim et al.   Gastroenterology Research and Practice

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

(2009) Kittichai Promrat et al.   HEPATOLOGY

Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease

(2009) Wei-Bing Song et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: Role of endotoxin

(2008) Ina Bergheim et al.   JOURNAL OF HEPATOLOGY